Ablacon has built a premier machine intelligence system to quantitatively and qualitatively understand and treat atrial fibrillation (AF).
Ablacon in the news
- Ablacon Announces Release of New and Improved Ablamap Technology Under Existing CE Mark
- Ablacon Announces Closing of a $10 Million Venture Debt Facility and $2 Million Equity Investment from Western Technology Investment; Josef Koblish and Melissa Kong to Join the Company
- Forbes lists Ablacon “25 Top Machine Learning Startups To Watch In 2019”
- Ablacon, Inc. Raises $21.5M Series A to Advance AI-Enabled Atrial Fibrillation Mapping System